对非特异性分离的终端阴茎异常的抗微生物药物的组合 - 一个随机临床试验
Raj Kumar1, Preetam Nath2,3, Anil Chandra Anand1
1Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar, 751 024, India.
概括
非特异性隔离终端阴茎异常 (NSITIA) 是常见的,但抗菌疗法没有显示出对症状治疗的治疗效益. 需要进一步的研究来了解NSITIA的管理和意义.
科学领域:
- 胃肠病学 胃肠病学
- 临床试验 临床试验
- 微生物学 微生物学
背景情况:
- 在结肠镜检查期间经常观察到非特异性隔离终端结核异常 (NSITIA),包括侵蚀,和结节性.
- 对于NSITIA的临床意义和最佳管理策略仍然不确定,需要进一步调查.
研究的目的:
- 为了比较组合抗微生物治疗与NSITIA患者的症状治疗的疗效.
- 在治疗后三个月,通过大肠直肠镜评估粘膜愈合率.
主要方法:
- 一项试点随机临床试验,涉及60名被诊断患有NSITIA的患者.
- 组A接受了组合抗微生物疗法 (利法西明,阿尔本达,丁达),而组B接受了症状治疗.
- 评估的结果包括临床症状,内镜检测结果和基线和随访时的组织病理学特征.
主要成果:
- 两个治疗组在临床症状 (92.4%vs. 88.8%),内镜检查结果 (88.5%vs. 81.5%) 和组织学特征 (76.5%vs. 70.4%) 中表现出相似的解决率.
- 在任何评估结果中,在抗微生物和症状治疗组之间没有观察到统计学上显著的差异.
结论:
- 大多数患有NSITIA的患者获得临床,内镜和组织病理学缓解,无论治疗方式如何.
- 在这项试点研究中,与症状治疗相比,组合抗微生物疗法对粘膜愈合率没有显著影响.
- 限制包括小样本大小和不完整的小肠评估,这表明需要进行更大规模的研究.
更多相关视频
08:33Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment
Published on: November 17, 2018
13.0K
12:58A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
9.0K
相关概念视频
01:27Combined Effects of Drugs: Synergism
4.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.0K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
209
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
209
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
157
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
157
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
449
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
449
01:29Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
01:29Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152